NCT02258321View on ClinicalTrials.gov

Phase 1 Study of Relative Bioavailability of PPI-668 New Tablet Versus Capsule Formulations

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

December 31, 2014

Conditions
Pharmacokinetic Assessments in Healthy Volunteers
Interventions
DRUG

PPI-668 tablet

DRUG

PPI-668 capsule

Trial Locations (1)

14202

Buffalo Clinical Research Center, Buffalo

Sponsors
All Listed Sponsors
lead

Presidio Pharmaceuticals, Inc.

INDUSTRY